A Phase 1b, Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of SEP-380135 in Adults With Schizophrenia or With a Major Depressive Episode Associated With Bipolar I or II Disorder or Major Depressive Disorder
Latest Information Update: 03 May 2026
At a glance
- Drugs SEP 380135 (Primary)
- Indications Major depressive disorder; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 03 May 2026 New trial record